BackgroundTo evaluate long-term IPSS score and urinary quality of life after radiotherapy for prostate cancer, in patients with prior history of surgical treatment for benign prostatic hyperplasia (BPH).MethodsIn this retrospective study, we reviewed medical records of patients treated in our department, between 2007 and 2013 with surgery for BPH followed by radiotherapy for localized prostate cancer. Patients were contacted to fill in IPSS questionnaire and they were also asked for urinary quality of life. Predictive factors known to be associated with bad urinary function were also analysed.ResultsFifty-nine patients were included in our study. Median age was 70 years. Median follow-up was 4.6 years. Median radiotherapy dose was 78 Gy (5 × 2 Gy/week). Thirty patients (48.5%) received hormone therapy in combination with RT. Main surgery indications were urinary symptoms (65%) and urinary retention (20%). Five-year biochemical-disease free survival was 75% and 5-year clinical relapse free survival was 84%. At the time of the study, the IPSS after radiotherapy was as follows: 0–7: 77.6%; 8–19:20.7%; 20–35: 1.7%. Urinary quality of life was satisfactory for 74.2% of patients. After multivariate analysis, a high dose of RT and a medical history of hypertension were associated with a poorer quality of urinary life (p = 0.04).ConclusionExternal radiotherapy remains an appropriate treatment option without a major risk for deterioration in urinary function in patient with antecedent surgery for BPH. High dose of RT and a medical history of hypertension were associated with a poorer quality of urinary life.

patients received RT. Surgery was performed in a subset of patients with 13.8% receiving STR and 9.4% receiving GTR. OS at 10 years was 42.2%, with a median follow-up time of 8.3 years. The most common histological diagnosis was diffuse large B-cell lymphoma (DLBCL 9680/3, 46%). Treatment era was associated with improved OS at 10 years, with 61.5% for 2001-2012 compared to 32.5% for 1973-2000 (P<0.01). Multivariate analysis adjusting for gender, year of diagnosis, and treatment regimens showed worse OS for age group 75+ (HR 3.067, 95% CI 2.023-4.721, P<0.01, using age group 18-44 as reference), but no association between improved OS with histological diagnosis of DLBCL (HR 0.978, 95% CI 0.734-1.302, PZ0.09). The delivery of RT (HR 0.747, 95% 0.542-1.041, PZ0.09) or surgery such as GTR (HR 0.648, 95% CI, PZ0.355) was not associated with statistically significant OS benefit. Conclusion: DLBCL was the most common histological category for primary spinal cord lymphoma, though no difference on OS was observed between DLBCL and other types. There was a trend for the benefit of RT on OS, though surgery was not found to be associated with improved survival. The longer OS with recent treatment era probably resulted from improved management strategies including better chemotherapeutic agents. Future study incorporating information on chemotherapy is needed to further validate our findings.Purpose/Objective(s): Among extranodal lymphomas, breast lymphoma is relatively well recognized, while the appropriate treatment of breast lymphomas has not been fully elucidated. The IELSG retrospective study Volume 96 Number 2S Supplement 2016 Poster Viewing E501

No abstract